Literature DB >> 17395766

Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s).

Rasmus Jorgensen1, Valentina Kubale, Milka Vrecl, Thue W Schwartz, Christian E Elling.   

Abstract

The glucagon-like peptide (GLP)-1 receptor is a promising target for the treatment of type 2 diabetes and obesity, and there is great interest in characterizing the pharmacology of the GLP-1 receptor and its ligands. In the present report, we have applied bioluminescence resonance energy transfer assays to measure agonist-induced recruitment of betaarrestins and G-protein-coupled receptor kinase (GRK) 2 to the GLP-1 receptor in addition to traditional measurements of second messenger generation. The peptide hormone oxyntomodulin is described in the literature as a full agonist on the glucagon and GLP-1 receptors. Surprisingly, despite being full agonists in GLP-1 receptor-mediated cAMP accumulation, oxyntomodulin and glucagon were observed to be partial agonists in recruiting betaarrestins and GRK2 to the GLP-1 receptor. We suggest that oxyntomodulin and glucagon are biased ligands on the GLP-1 receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17395766     DOI: 10.1124/jpet.107.120006

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  54 in total

Review 1.  Probing heterotrimeric G protein activation: applications to biased ligands.

Authors:  Colette Denis; Aude Saulière; Segolene Galandrin; Jean-Michel Sénard; Céline Galés
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 3.  β-Arrestins: multifunctional signaling adaptors in type 2 diabetes.

Authors:  Xiaotao Feng; Wenjian Wang; Jibo Liu; Yi Liu
Journal:  Mol Biol Rep       Date:  2010-11-18       Impact factor: 2.316

4.  PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells.

Authors:  C S Walker; T Sundrum; D L Hay
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 5.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 6.  Optical approaches for single-cell and subcellular analysis of GPCR-G protein signaling.

Authors:  Dinesh Kankanamge; Kasun Ratnayake; Kanishka Senarath; Mithila Tennakoon; Elise Harmon; Ajith Karunarathne
Journal:  Anal Bioanal Chem       Date:  2019-03-30       Impact factor: 4.142

Review 7.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

8.  Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

Authors:  Diana L Williams; Denis G Baskin; Michael W Schwartz
Journal:  Endocrinology       Date:  2008-12-12       Impact factor: 4.736

9.  A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.

Authors:  Lindsey C Morris; Emily L Days; Maxine Turney; Dehui Mi; Craig W Lindsley; C David Weaver; Kevin D Niswender
Journal:  J Biomol Screen       Date:  2014-02-13

10.  Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling.

Authors:  Ib V Klewe; Søren M Nielsen; Louise Tarpø; Eneko Urizar; Concetta Dipace; Jonathan A Javitch; Ulrik Gether; Jan Egebjerg; Kenneth V Christensen
Journal:  Neuropharmacology       Date:  2008-04-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.